JP2003528828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528828A5 JP2003528828A5 JP2001563480A JP2001563480A JP2003528828A5 JP 2003528828 A5 JP2003528828 A5 JP 2003528828A5 JP 2001563480 A JP2001563480 A JP 2001563480A JP 2001563480 A JP2001563480 A JP 2001563480A JP 2003528828 A5 JP2003528828 A5 JP 2003528828A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- formula
- alkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- -1 hydrogen Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 0 C=*C=C(C(N)=O)N(CCC1)C1=O Chemical compound C=*C=C(C(N)=O)N(CCC1)C1=O 0.000 description 1
- HPHUVLMMVZITSG-UHFFFAOYSA-N CCC(C(N)=O)N(CCC1)C1=O Chemical compound CCC(C(N)=O)N(CCC1)C1=O HPHUVLMMVZITSG-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004297.8 | 2000-02-23 | ||
| GBGB0004297.8A GB0004297D0 (en) | 2000-02-23 | 2000-02-23 | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| PCT/EP2001/001956 WO2001064637A1 (en) | 2000-02-23 | 2001-02-21 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007102379A Division JP4769756B2 (ja) | 2000-02-23 | 2007-04-10 | ２−オキソ−１−ピロリジン誘導体、それらの製造法、およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003528828A JP2003528828A (ja) | 2003-09-30 |
| JP2003528828A5 true JP2003528828A5 (enExample) | 2007-06-07 |
| JP4081275B2 JP4081275B2 (ja) | 2008-04-23 |
Family
ID=9886259
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001561734A Expired - Lifetime JP4121744B2 (ja) | 2000-02-23 | 2001-02-21 | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
| JP2001563480A Expired - Fee Related JP4081275B2 (ja) | 2000-02-23 | 2001-02-21 | ２−オキソ−１−ピロリジン誘導体、それらの製造法、およびそれらの使用 |
| JP2005217442A Expired - Lifetime JP4938259B2 (ja) | 2000-02-23 | 2005-07-27 | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
| JP2005217433A Pending JP2006022107A (ja) | 2000-02-23 | 2005-07-27 | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
| JP2007102379A Expired - Fee Related JP4769756B2 (ja) | 2000-02-23 | 2007-04-10 | ２−オキソ−１−ピロリジン誘導体、それらの製造法、およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001561734A Expired - Lifetime JP4121744B2 (ja) | 2000-02-23 | 2001-02-21 | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005217442A Expired - Lifetime JP4938259B2 (ja) | 2000-02-23 | 2005-07-27 | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
| JP2005217433A Pending JP2006022107A (ja) | 2000-02-23 | 2005-07-27 | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
| JP2007102379A Expired - Fee Related JP4769756B2 (ja) | 2000-02-23 | 2007-04-10 | ２−オキソ−１−ピロリジン誘導体、それらの製造法、およびそれらの使用 |
Country Status (43)
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365093B2 (en) * | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6686477B2 (en) * | 2000-09-29 | 2004-02-03 | Eastman Chemical Company | Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same |
| EP1379236A4 (en) * | 2001-02-23 | 2009-01-21 | Ucb Sa | TREATMENT OF TICS, TREMOR AND RELATED DISORDER |
| US7122682B2 (en) * | 2001-08-10 | 2006-10-17 | Ucb, S.A. | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues |
| US20040242671A1 (en) * | 2001-10-08 | 2004-12-02 | Renee Grimee | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug |
| ES2334650T3 (es) | 2001-10-16 | 2010-03-15 | Memory Pharmaceuticals Corporation | Derivados de 4(4-alkoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos. |
| WO2003094913A1 (en) * | 2002-05-14 | 2003-11-20 | Ucb, S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug |
| AU2004204338A1 (en) | 2003-01-13 | 2004-07-29 | Ucb | Hydrogenation catalysts |
| WO2004069796A2 (en) * | 2003-02-03 | 2004-08-19 | Teva Pharmaceutical Industries Ltd. | Process for producing levetiracetam |
| ES2214147B1 (es) | 2003-02-28 | 2005-10-01 | Farma-Lepori S.A. | Procedimiento de obtencion de un agente antiepileptico. |
| TR200503397T1 (tr) * | 2003-03-18 | 2007-03-21 | Hetero Drugs Limited | Levetirasetam'ın yeni kristal formları. |
| RU2232578C1 (ru) * | 2003-04-10 | 2004-07-20 | Ахапкина Валентина Ивановна | Вещество, обладающее антидепрессивной активностью |
| WO2004094375A2 (en) | 2003-04-16 | 2004-11-04 | Memory Pharmaceuticals Corporation | 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors |
| US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
| WO2005023763A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Process for the preparation of pure levetiracetam |
| DK1667967T3 (da) | 2003-09-24 | 2012-10-08 | Ucb Pharma Sa | Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater |
| ES2323313T3 (es) | 2003-12-02 | 2009-07-13 | Ucb Pharma, S.A. | Derivados de imidazol, procedimientos para prepararlos y sus usos. |
| KR101159870B1 (ko) * | 2004-06-11 | 2012-06-25 | 유씨비 소시에떼아노님 | 분자내 알릴화에 의해 2-옥소-1-피롤리딘 유도체를제조하는 방법 |
| WO2006000904A2 (en) * | 2004-06-21 | 2006-01-05 | Warner-Lambert Company Llc | Preparation of pregabalin and related compounds |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| WO2006044955A1 (en) * | 2004-10-20 | 2006-04-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| CA2488325C (en) * | 2004-11-22 | 2010-08-24 | Apotex Pharmachem Inc. | Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| ES2441178T3 (es) | 2005-06-01 | 2014-02-03 | Ucb Pharma, S.A. | Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central |
| EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| EP1926710B1 (en) * | 2005-09-15 | 2014-11-12 | UCB Pharma S.A. | 4-Substituted pyrrolidin-2-ones and their use |
| JP2007153755A (ja) * | 2005-12-01 | 2007-06-21 | Gifu Univ | プロリン類縁体 |
| EP1993998B1 (en) * | 2005-12-07 | 2013-08-21 | UCB Pharma, S.A. | 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses |
| US8338621B2 (en) | 2005-12-21 | 2012-12-25 | Ucb S.A. | Process for the preparation of 2-oxo-1-pyrrolidine derivatives |
| LV13630B (en) * | 2006-03-16 | 2007-12-20 | Olainfarm As | Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone |
| US8211936B2 (en) * | 2006-06-08 | 2012-07-03 | Ucb Pharma, S.A. | Co-crystals of pyrrolidinones |
| EP2462990B2 (en) | 2006-06-15 | 2018-04-18 | UCB Pharma GmbH | Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| GEP20125425B (en) * | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| US8828665B2 (en) | 2007-02-16 | 2014-09-09 | Ark Diagnostics, Inc. | Compounds and methods for use in detecting gabapentin |
| EP2152262A2 (en) * | 2007-04-27 | 2010-02-17 | UCB Pharma, S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
| US20090082422A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched levetiracetam |
| CA2715685C (en) * | 2008-03-03 | 2015-04-28 | Eric Schenkel | Pharmaceutical solutions, process of preparation and therapeutic uses |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| WO2010002869A1 (en) * | 2008-07-01 | 2010-01-07 | Concert Pharmaceuticals, Inc. | 2-oxo-1-pyrrolidine derivatives |
| EP2147911A1 (en) | 2008-07-24 | 2010-01-27 | ZaCh System S.p.A. | Process for the preparation of levetiracetam |
| JP4644881B2 (ja) | 2008-09-19 | 2011-03-09 | 高砂香料工業株式会社 | ルテニウム錯体の製造方法 |
| CN107243007A (zh) | 2008-10-16 | 2017-10-13 | 约翰斯.霍普金斯大学 | 改善认知功能的方法和组合物 |
| WO2010048423A1 (en) * | 2008-10-24 | 2010-04-29 | Ark Diagnostics, Inc. | Levetiracetam immunoassays |
| US8722715B2 (en) * | 2008-11-07 | 2014-05-13 | NovaBay Pharmaceuticals | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions |
| CN104208714A (zh) * | 2008-11-18 | 2014-12-17 | Ucb医药有限公司 | 含有2-氧代-1-吡咯烷衍生物的延长释放制剂 |
| US8460712B2 (en) * | 2008-11-18 | 2013-06-11 | Ucb Pharma, S.A. | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate |
| FR2939311A1 (fr) * | 2008-12-08 | 2010-06-11 | Oreal | Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant |
| WO2010089372A1 (en) | 2009-02-09 | 2010-08-12 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising brivaracetam |
| US8846411B2 (en) * | 2009-06-11 | 2014-09-30 | Microgenics Corporation | Derivatives, reagents, and immunoassay for detecting levetiracetam |
| US20120171125A1 (en) | 2009-08-07 | 2012-07-05 | Ucb Pharma, S.A. | Methods for Enhancing the Cognitive Function |
| US7939676B2 (en) | 2009-09-17 | 2011-05-10 | Zach System S.P.A. | Process for the preparation of levetiracetam |
| US8487591B1 (en) | 2009-12-31 | 2013-07-16 | Cirrus Logic, Inc. | Power control system with power drop out immunity and uncompromised startup time |
| HRP20160263T1 (hr) | 2009-10-23 | 2016-04-08 | Ucb Biopharma Sprl | Derivati 2-okso-1-pirolidinil imidazotiadiazola |
| PL389364A1 (pl) | 2009-10-23 | 2011-04-26 | Uniwersytet Jagielloński | Nowe zastosowanie pochodnych 2-pirolidonu |
| CN102905532A (zh) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| FR2961099B1 (fr) | 2010-06-09 | 2012-06-15 | Oreal | Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques |
| FR2961098A1 (fr) | 2010-06-09 | 2011-12-16 | Oreal | Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques |
| FR2961101B1 (fr) | 2010-06-09 | 2013-01-25 | Oreal | Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques |
| US8466297B2 (en) | 2010-11-01 | 2013-06-18 | Milan Soukup | Manufacturing process for (S)-Pregabalin |
| MX383953B (es) | 2010-11-15 | 2025-03-14 | Agenebio Inc | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| CA2826765C (en) * | 2011-02-09 | 2021-04-06 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2831830C (en) | 2011-04-18 | 2017-12-12 | Ucb Pharma, S.A. | 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives |
| CN103906745B (zh) | 2011-09-30 | 2017-08-25 | 塔夫斯大学 | 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法 |
| CN104870421A (zh) * | 2011-12-27 | 2015-08-26 | 比皮艾思药物研发有限公司 | 用于预防或治疗als的苯基氨基甲酸酯化合物 |
| TW201408293A (zh) * | 2012-07-05 | 2014-03-01 | Merz Pharma Gmbh & Co Kgaa | (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途 |
| TW201408294A (zh) * | 2012-07-05 | 2014-03-01 | Merz Pharma Gmbh & Co Kgaa | (r)-苯基披喇瑟盪於治療帕金森氏症之用除 |
| AU2013323188B2 (en) | 2012-09-28 | 2018-04-19 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014088984A1 (en) * | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| WO2014087367A2 (en) * | 2012-12-09 | 2014-06-12 | Mahesh Kandula | Compositions and methods for the treatment of neurological diseases and its associated complications |
| EP2945942B1 (en) | 2013-01-18 | 2018-05-09 | ARK Diagnostics, Inc. | Voriconazole immunoassays |
| ES2674704T3 (es) | 2013-02-13 | 2018-07-03 | Ark Diagnostics, Inc. | Inmunoensayos de posaconazol |
| US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| ES2684368T3 (es) | 2013-03-13 | 2018-10-02 | Tufts University | Derivados del nucleósido uridina, composiciones y métodos de uso |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN103342672B (zh) * | 2013-07-02 | 2015-12-23 | 扬州大学 | 取代吡咯烷-2-酮的新合成方法 |
| JP6465634B2 (ja) * | 2013-12-05 | 2019-02-06 | 株式会社日本触媒 | 環状アミド基含有重合体 |
| JP6453632B2 (ja) * | 2013-12-05 | 2019-01-16 | 株式会社日本触媒 | 環状アミドアクリレート含有組成物およびその製造方法 |
| MX381561B (es) | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
| ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
| AU2015208233B2 (en) | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| CN104098497B (zh) * | 2014-06-17 | 2016-04-13 | 王庚禹 | 一种新的酰胺类化合物 |
| WO2016075082A1 (en) | 2014-11-10 | 2016-05-19 | Sandoz Ag | Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam |
| EP3258921A1 (en) | 2015-02-20 | 2017-12-27 | UCB Biopharma SPRL | Combination treatment |
| CN108689968B (zh) * | 2015-05-25 | 2020-09-15 | 苏州鹏旭医药科技有限公司 | 两种化合物及其制备方法和在合成布瓦西坦中的用途 |
| JP6872500B2 (ja) * | 2015-05-25 | 2021-05-19 | エステベ・キミカ・ソシエダッド・アノニマＥｓｔｅｖｅ Ｑｕｉｍｉｃａ， Ｓ．Ａ． | ブリバラセタムを製造する方法 |
| CN106365986B (zh) * | 2015-07-21 | 2019-01-08 | 苏州鹏旭医药科技有限公司 | 化合物及其制备方法和在合成布瓦西坦中的用途 |
| PT3310800T (pt) | 2015-06-19 | 2022-03-21 | Centurion Biopharma Corp | Sistemas de administração para a libertação controlada de fármacos |
| US10815242B2 (en) | 2015-06-19 | 2020-10-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2017076737A1 (en) | 2015-11-03 | 2017-05-11 | Ucb Biopharma Sprl | Continuous process for preparing brivaracetam |
| PT3371150T (pt) | 2015-11-03 | 2021-11-05 | Ucb Biopharma Sprl | Processo de preparação do brivaracetam |
| CN106748748B (zh) * | 2015-11-10 | 2021-08-24 | 成都国为生物医药有限公司 | 一种布瓦西坦的制备方法及其中间体 |
| CN105646319B (zh) * | 2015-12-30 | 2018-05-18 | 佛山市隆信医药科技有限公司 | 一种布瓦西坦的制备方法 |
| AU2016381366A1 (en) | 2015-12-30 | 2018-06-28 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| EP3452447A4 (en) | 2016-05-03 | 2019-12-18 | The Regents of The University of California | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS |
| RU2629117C1 (ru) * | 2016-06-14 | 2017-08-24 | Сизов Владимир Владимирович | Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида |
| CN107513031B (zh) * | 2016-06-16 | 2022-08-02 | 上海医药集团股份有限公司 | 一种2-氧代-1-吡咯烷手性衍生物的制备方法 |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2018210393A1 (en) | 2017-01-20 | 2019-07-25 | The Regents Of The University Of California | Inhibitors of the N-terminal domain of the androgen receptor |
| CN106866483A (zh) * | 2017-02-05 | 2017-06-20 | 苏州鹏旭医药科技有限公司 | 布瓦西坦的晶型c及其制备方法 |
| WO2018141276A1 (zh) * | 2017-02-05 | 2018-08-09 | 苏州鹏旭医药科技有限公司 | 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法 |
| CN108503610B (zh) | 2017-02-24 | 2019-09-13 | 北京艾百诺医药股份有限公司 | 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法 |
| CN108658831B (zh) * | 2017-03-30 | 2021-11-05 | 江苏豪森药业集团有限公司 | 2-氧代-1-吡咯烷衍生物或其盐的制备方法 |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| KR20250151619A (ko) | 2017-06-30 | 2025-10-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 모발 성장을 조절하기 위한 조성물 및 방법 |
| US20200290978A1 (en) | 2017-09-26 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| CN107793342A (zh) * | 2017-10-19 | 2018-03-13 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦的制备方法 |
| CN107721896A (zh) * | 2017-10-19 | 2018-02-23 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦的中间体的制备方法 |
| US11377473B2 (en) | 2017-11-30 | 2022-07-05 | Centurion Biopharma Corporation | Albumin-binding prodrugs of auristatin E derivatives |
| IL305268A (en) | 2017-11-30 | 2023-10-01 | Centurion Biopharma Corp | Maytansinoid-based drug delivery systems |
| US11708329B2 (en) | 2018-01-30 | 2023-07-25 | The Regents Of The University Of California | Inhibitors of the WNT/beta-catenin pathway |
| CN108147988B (zh) * | 2018-02-13 | 2020-10-02 | 扬州奥锐特药业有限公司 | 一种高手性纯度内酰胺化合物的制备方法 |
| CN108530402B (zh) * | 2018-04-10 | 2020-06-26 | 浙江工业大学 | 一种(R)-3-丙基-γ-丁内酯的制备方法 |
| EP3566760A1 (en) * | 2018-05-07 | 2019-11-13 | Universite Libre De Bruxelles | Method for nucleating crystals from a solution in a capillary tube |
| US11286266B2 (en) | 2018-05-08 | 2022-03-29 | UCB Biopharma SRL | 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives |
| CA3104478A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN110615744B (zh) | 2018-06-20 | 2023-01-06 | 上海朴颐化学科技有限公司 | 一种布瓦西坦中间体及其制备方法 |
| EP3813841B1 (en) | 2018-06-29 | 2025-08-13 | The Regents Of The University Of California | New molecular tweezers against neurological disorders and viral infections |
| RU2699669C1 (ru) * | 2018-07-04 | 2019-09-09 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новые составы N-карбамоилметил-4-фенил-2-пирролидона |
| AU2019310595B2 (en) | 2018-07-27 | 2022-11-24 | 1200 Pharma Llc | CDK inhibitors and uses thereof |
| EP3867223B1 (en) | 2018-10-17 | 2025-12-10 | The Regents of the University of California | Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof |
| US11214568B2 (en) | 2018-10-18 | 2022-01-04 | California Institute Of Technology | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same |
| CN112930350A (zh) | 2018-10-31 | 2021-06-08 | 尹图赛利有限公司 | 稠合杂环苯并二氮杂䓬衍生物及其用途 |
| EP3890833B1 (en) | 2018-12-04 | 2023-06-07 | Metys Pharmaceuticals AG | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio |
| EP3944739A4 (en) | 2019-02-25 | 2023-06-21 | The Regents of the University of California | METHOD OF FRAGMENTATION OF CARBON-CARBON BONDS |
| CN109932442A (zh) * | 2019-03-04 | 2019-06-25 | 成都美域高制药有限公司 | 一种布瓦西坦异构体的检测方法 |
| CA3134779A1 (en) | 2019-03-25 | 2020-10-01 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| AU2020286381C1 (en) | 2019-06-04 | 2025-07-10 | Hager Biosciences, Llc | Imidazolo derivatives, compositions and methods as orexin antagonists |
| CN110357752A (zh) * | 2019-08-15 | 2019-10-22 | 中国工程物理研究院化工材料研究所 | 一种快速制备均匀包覆含能材料的方法 |
| RU2732245C1 (ru) * | 2019-08-30 | 2020-09-14 | Ооо "Валента-Интеллект" | Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения |
| CN110551050A (zh) * | 2019-09-02 | 2019-12-10 | 南通大学 | 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法 |
| US10781170B1 (en) | 2019-10-21 | 2020-09-22 | Divi's Laboratories Ltd. | Process for preparing Brivaracetam |
| WO2021142132A1 (en) | 2020-01-07 | 2021-07-15 | The Trustees Of Princeton University | Compositions and methods for treatment of disease by manipulation of serine metabolism |
| EP4087847A4 (en) | 2020-01-10 | 2024-02-28 | The Regents of the University of California | Compositions and methods for the treatment of neurodegenerative diseases |
| US20230174460A1 (en) | 2020-04-21 | 2023-06-08 | President And Fellowes Of Harvard College | Afmt analogs and their use in methods of treating parkinson's disease |
| LV15614A (lv) | 2020-07-30 | 2022-02-20 | Latvijas Organiskās Sintēzes Institūts | 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi |
| US20230271918A1 (en) | 2020-08-10 | 2023-08-31 | Dana-Farber Cancer Institute, Inc. | Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28 |
| WO2022035806A1 (en) | 2020-08-10 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28 |
| CA3191164A1 (en) | 2020-08-10 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28 |
| EP4225285A4 (en) * | 2020-10-06 | 2024-11-20 | D.E. Shaw Research, LLC | LACTAM COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS |
| EP4232161A1 (en) | 2020-10-23 | 2023-08-30 | Dana-Farber Cancer Institute, Inc. | Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer |
| US20240058344A1 (en) | 2020-12-18 | 2024-02-22 | Cornell University | Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak |
| CA3202532A1 (en) | 2020-12-21 | 2022-06-30 | Shek Hang Benedict LAW | Peptide-linked drug delivery system |
| US20240132480A1 (en) | 2021-01-08 | 2024-04-25 | Cornell University | Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase |
| US11400074B1 (en) | 2021-02-01 | 2022-08-02 | Divi's Laboratories Ltd. | Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam |
| US11384050B1 (en) * | 2021-02-03 | 2022-07-12 | Vitaworks Ip, Llc | Method for preparing levetiracetam and intermediates thereof |
| CN114948953A (zh) * | 2021-06-29 | 2022-08-30 | 四川大学华西医院 | 一种杂原子取代芳香类化合物及其盐的用途 |
| CN113511994B (zh) * | 2021-08-16 | 2023-03-21 | 江苏八巨药业有限公司 | 一种左乙拉西坦的制备方法 |
| CN114634437B (zh) * | 2022-03-29 | 2023-05-30 | 武汉氟本氘合新材料科技有限公司 | 一种布瓦西坦的简易制备方法 |
| US11884623B2 (en) | 2022-05-23 | 2024-01-30 | Divi's Laboratories Ltd. | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam |
| WO2023250157A1 (en) | 2022-06-24 | 2023-12-28 | Cornell University | Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase |
| CN119604494A (zh) | 2022-07-13 | 2025-03-11 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP4582412A1 (en) * | 2022-08-31 | 2025-07-09 | Korea University Research and Business Foundation | Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor |
| WO2024163711A1 (en) | 2023-02-02 | 2024-08-08 | Osmoses Inc. | Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation |
| CN116041240B (zh) | 2023-02-17 | 2024-04-09 | 扬州奥锐特药业有限公司 | 布立西坦中间体的不对称催化氢化合成方法 |
| EP4431086A1 (en) | 2023-03-16 | 2024-09-18 | Adalvo Limited | Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide |
| WO2025078883A2 (en) | 2023-05-06 | 2025-04-17 | Prepaire Labs Limited | Organic compound (oxime) to combat chemical warfare agents |
| TW202525266A (zh) | 2023-09-18 | 2025-07-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 可電離類脂質組成物及其治療用途 |
| WO2025072893A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US20250162981A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025231452A1 (en) | 2024-05-02 | 2025-11-06 | Martinez Montemayor Michelle | Ergosterol peroxide derivatives and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD92031A (enExample) * | ||||
| DE92031C (enExample) | ||||
| US2836599A (en) * | 1957-03-07 | 1958-05-27 | Aerojet General Co | Nu-(carboxyalkyl) dinitro lactams |
| GB1039113A (en) | 1964-08-06 | 1966-08-17 | Ucb Sa | New n-substituted lactams |
| GB1309692A (en) * | 1970-02-13 | 1973-03-14 | Ucb Sa | N-substituted lactams |
| US4008281A (en) | 1973-12-03 | 1977-02-15 | Monsanto Company | Asymmetric catalysis |
| HU177239B (hu) | 1974-10-15 | 1981-08-28 | Monsanto Co | Eljárás N-acetamido-L-alanin-származékok előállítására α-acetamido-akrilsav-származékok aszimmetrikus katalitikus hídrogénezésével |
| DE3371510D1 (en) * | 1982-03-24 | 1987-06-19 | Prodes Sa | New 2-oxo-1-pyrrolidineacetic acid esters, their methods of production and therapeutic compositions containing the same |
| EP0089900B1 (en) * | 1982-03-24 | 1985-12-27 | Prodes S.A. | New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts |
| GB8412358D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| CN1015542B (zh) * | 1984-05-15 | 1992-02-19 | 尤西比公司 | (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| JPS60166692A (ja) | 1984-09-28 | 1985-08-29 | Kazuo Achinami | 新規不斉還元試薬 |
| CH666891A5 (de) * | 1985-11-26 | 1988-08-31 | Lonza Ag | 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung. |
| DE3719873A1 (de) * | 1987-06-13 | 1988-12-29 | Basf Ag | Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure |
| JPH0757758B2 (ja) | 1988-10-24 | 1995-06-21 | 高砂香料工業株式会社 | ルテニウム―ホスフィン錯体 |
| GB8827389D0 (en) | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| CZ281170B6 (cs) * | 1991-05-02 | 1996-07-17 | Daiichi Pharmaceutical Co., Ltd | Léčivo pro léčení demence |
| US5171892A (en) | 1991-07-02 | 1992-12-15 | E. I. Du Pont De Nemours And Company | Chiral phospholanes via chiral 1,4-diol cyclic sulfates |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| EP0645135A1 (de) * | 1993-09-29 | 1995-03-29 | Solco Basel AG | Hämodialysat enthaltendes Sonnenschutzmittel |
| JPH1180027A (ja) * | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
| TW544311B (en) * | 1998-08-06 | 2003-08-01 | Daiichi Seiyaku Co | Therapeutic or preventive agent for intractable epilepsies |
| CZ20001055A3 (cs) * | 1998-10-02 | 2000-08-16 | Dupont Pharmaceuticals Company | Nové laktamové inhibitory metaloproteázy |
| WO2001039779A1 (en) | 1999-12-01 | 2001-06-07 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6686477B2 (en) | 2000-09-29 | 2004-02-03 | Eastman Chemical Company | Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same |
-
2000
- 2000-02-23 GB GBGB0004297.8A patent/GB0004297D0/en not_active Ceased
-
2001
- 2001-02-21 CZ CZ2002-2850A patent/CZ304420B6/cs not_active IP Right Cessation
- 2001-02-21 JP JP2001561734A patent/JP4121744B2/ja not_active Expired - Lifetime
- 2001-02-21 ME MEP-61/09A patent/MEP6109A/xx unknown
- 2001-02-21 AU AU2001252144A patent/AU2001252144C1/en not_active Expired
- 2001-02-21 CA CA002401033A patent/CA2401033C/en not_active Expired - Lifetime
- 2001-02-21 ES ES01925354T patent/ES2248307T3/es not_active Expired - Lifetime
- 2001-02-21 KR KR1020057016175A patent/KR100720784B1/ko not_active Expired - Lifetime
- 2001-02-21 CO CO01013822A patent/CO5271667A1/es not_active Application Discontinuation
- 2001-02-21 AT AT01940256T patent/ATE282592T1/de active
- 2001-02-21 EP EP04007878A patent/EP1452524B1/en not_active Expired - Lifetime
- 2001-02-21 PL PL365159A patent/PL210121B1/pl unknown
- 2001-02-21 HU HU0500902A patent/HU230270B1/hu active Protection Beyond IP Right Term
- 2001-02-21 MX MXPA02008056A patent/MXPA02008056A/es active IP Right Grant
- 2001-02-21 ES ES01940256T patent/ES2231501T3/es not_active Expired - Lifetime
- 2001-02-21 DK DK04007733T patent/DK1447399T3/da active
- 2001-02-21 HU HU0300196A patent/HUP0300196A3/hu unknown
- 2001-02-21 DK DK04007878.4T patent/DK1452524T3/da active
- 2001-02-21 CO CO01013823A patent/CO5280059A1/es not_active Application Discontinuation
- 2001-02-21 IL IL15084201A patent/IL150842A0/xx active IP Right Grant
- 2001-02-21 DE DE60140222T patent/DE60140222D1/de not_active Expired - Lifetime
- 2001-02-21 CN CNB2005100713086A patent/CN1303066C/zh not_active Expired - Fee Related
- 2001-02-21 DE DE60143493T patent/DE60143493D1/de not_active Expired - Lifetime
- 2001-02-21 EP EP05013657A patent/EP1604979A1/en not_active Withdrawn
- 2001-02-21 MY MYPI20010775A patent/MY138966A/en unknown
- 2001-02-21 ES ES04008270T patent/ES2355140T3/es not_active Expired - Lifetime
- 2001-02-21 BR BRPI0108664A patent/BRPI0108664B8/pt not_active IP Right Cessation
- 2001-02-21 AT AT01925354T patent/ATE304999T1/de active
- 2001-02-21 DE DE60113514T patent/DE60113514T2/de not_active Expired - Lifetime
- 2001-02-21 DE DE60119397T patent/DE60119397T2/de not_active Expired - Lifetime
- 2001-02-21 EG EG20010172A patent/EG24375A/xx active
- 2001-02-21 NZ NZ520448A patent/NZ520448A/en not_active IP Right Cessation
- 2001-02-21 CZ CZ2005-763A patent/CZ304702B6/cs unknown
- 2001-02-21 EP EP05012174A patent/EP1577296A1/en not_active Withdrawn
- 2001-02-21 HK HK03104916.0A patent/HK1052516B/zh not_active IP Right Cessation
- 2001-02-21 IL IL15075701A patent/IL150757A0/xx not_active IP Right Cessation
- 2001-02-21 RS YUP-631/02A patent/RS50454B/sr unknown
- 2001-02-21 RU RU2006125756/04A patent/RU2355680C2/ru not_active IP Right Cessation
- 2001-02-21 HK HK03104935.7A patent/HK1052695B/zh not_active IP Right Cessation
- 2001-02-21 SI SI200130451T patent/SI1265862T1/sl unknown
- 2001-02-21 WO PCT/EP2001/001992 patent/WO2001062726A2/en not_active Ceased
- 2001-02-21 PT PT04007733T patent/PT1447399E/pt unknown
- 2001-02-21 MY MYPI20052965A patent/MY140593A/en unknown
- 2001-02-21 EP EP04007733A patent/EP1447399B9/en not_active Expired - Lifetime
- 2001-02-21 KR KR1020057016174A patent/KR100681580B1/ko not_active Expired - Fee Related
- 2001-02-21 RU RU2002124522A patent/RU2291860C3/ru active
- 2001-02-21 CN CNA2005100999524A patent/CN1740151A/zh active Pending
- 2001-02-21 CN CNB018054455A patent/CN1208319C/zh not_active Expired - Lifetime
- 2001-02-21 EP EP01925354A patent/EP1265862B1/en not_active Expired - Lifetime
- 2001-02-21 MY MYPI20010763A patent/MY127149A/en unknown
- 2001-02-21 EP EP04030940A patent/EP1577295A1/en not_active Withdrawn
- 2001-02-21 MY MYPI20053631A patent/MY139420A/en unknown
- 2001-02-21 PL PL380061A patent/PL213669B1/pl unknown
- 2001-02-21 US US10/204,275 patent/US6713635B2/en not_active Expired - Fee Related
- 2001-02-21 AU AU73896/01A patent/AU778510B2/en not_active Ceased
- 2001-02-21 RO ROA200201076A patent/RO121559B1/ro unknown
- 2001-02-21 CN CNA2005100999539A patent/CN1740150A/zh active Pending
- 2001-02-21 HU HU0204526A patent/HU229514B1/hu unknown
- 2001-02-21 PL PL359388A patent/PL212197B1/pl not_active IP Right Cessation
- 2001-02-21 BR BR0108657-0A patent/BR0108657A/pt not_active IP Right Cessation
- 2001-02-21 RS YUP-632/02A patent/RS50455B/sr unknown
- 2001-02-21 AT AT04008270T patent/ATE488500T1/de not_active IP Right Cessation
- 2001-02-21 AU AU5214401A patent/AU5214401A/xx active Pending
- 2001-02-21 DE DE60107216T patent/DE60107216T2/de not_active Expired - Lifetime
- 2001-02-21 KR KR1020027010984A patent/KR100759145B1/ko not_active Expired - Fee Related
- 2001-02-21 CA CA002401048A patent/CA2401048C/en not_active Expired - Fee Related
- 2001-02-21 MX MXPA02008206A patent/MXPA02008206A/es active IP Right Grant
- 2001-02-21 AT AT04007878T patent/ATE445597T1/de active
- 2001-02-21 ES ES04007878T patent/ES2334998T3/es not_active Expired - Lifetime
- 2001-02-21 CZ CZ20022849A patent/CZ20022849A3/cs unknown
- 2001-02-21 RO ROA200201141A patent/RO121597B1/ro unknown
- 2001-02-21 JP JP2001563480A patent/JP4081275B2/ja not_active Expired - Fee Related
- 2001-02-21 AT AT04007733T patent/ATE325093T1/de active
- 2001-02-21 EP EP04008270A patent/EP1477478B1/en not_active Expired - Lifetime
- 2001-02-21 CN CNB018055079A patent/CN1179944C/zh not_active Expired - Fee Related
- 2001-02-21 EP EP01940256A patent/EP1263727B1/en not_active Expired - Lifetime
- 2001-02-21 ES ES04007733T patent/ES2264060T3/es not_active Expired - Lifetime
- 2001-02-21 KR KR1020027010960A patent/KR100816185B1/ko not_active Expired - Lifetime
- 2001-02-21 DK DK01925354T patent/DK1265862T3/da active
- 2001-02-21 PT PT04007878T patent/PT1452524E/pt unknown
- 2001-02-21 WO PCT/EP2001/001956 patent/WO2001064637A1/en not_active Ceased
- 2001-02-21 RU RU2002124865/04A patent/RU2292336C2/ru not_active IP Right Cessation
- 2001-03-13 TW TW095112075A patent/TW200626545A/zh unknown
- 2001-03-13 TW TW095112074A patent/TW200626544A/zh unknown
- 2001-04-01 SA SA01220027A patent/SA01220027B1/ar unknown
- 2001-04-24 SA SA01220078A patent/SA01220078B1/ar unknown
-
2002
- 2002-02-21 US US10/204,266 patent/US6784197B2/en not_active Expired - Lifetime
- 2002-07-16 ZA ZA200205671A patent/ZA200205671B/en unknown
- 2002-07-16 IS IS6472A patent/IS2119B/is unknown
- 2002-07-22 ZA ZA200205837A patent/ZA200205837B/en unknown
- 2002-07-22 IL IL150842A patent/IL150842A/en unknown
- 2002-07-23 IS IS6481A patent/IS2176B/is unknown
- 2002-08-14 BG BG107004A patent/BG65923B1/bg unknown
- 2002-08-20 BG BG109297A patent/BG109297A/en unknown
- 2002-08-20 BG BG107016A patent/BG65783B1/bg unknown
- 2002-08-22 NO NO20023995A patent/NO324051B1/no not_active IP Right Cessation
- 2002-08-22 NO NO20023997A patent/NO324485B1/no active Protection Beyond IP Right Term
- 2002-08-26 CU CU20020181A patent/CU23293B7/es not_active IP Right Cessation
- 2002-08-26 CU CU20020180A patent/CU23201A3/es unknown
-
2003
- 2003-07-01 US US10/609,544 patent/US6858740B2/en not_active Expired - Fee Related
- 2003-10-28 US US10/694,090 patent/US6806287B2/en not_active Expired - Lifetime
- 2003-10-28 US US10/693,917 patent/US6911461B2/en active Active
-
2004
- 2004-04-15 US US10/824,345 patent/US6969770B2/en not_active Expired - Fee Related
-
2005
- 2005-01-04 US US11/028,039 patent/US7217826B2/en not_active Expired - Fee Related
- 2005-01-27 US US11/043,145 patent/US20050171187A1/en not_active Abandoned
- 2005-01-27 US US11/043,176 patent/US7358276B2/en not_active Expired - Lifetime
- 2005-02-09 IL IL166768A patent/IL166768A/en not_active IP Right Cessation
- 2005-02-17 AU AU2005200717A patent/AU2005200717B2/en not_active Ceased
- 2005-02-17 AU AU2005200718A patent/AU2005200718B2/en not_active Ceased
- 2005-06-29 IS IS7920A patent/IS7920A/is unknown
- 2005-06-29 IS IS7922A patent/IS2754B/is unknown
- 2005-06-29 IS IS7919A patent/IS7919A/is unknown
- 2005-06-29 IS IS7923A patent/IS7923A/is unknown
- 2005-06-29 IS IS7918A patent/IS7918A/is unknown
- 2005-06-29 IS IS7921A patent/IS7921A/is unknown
- 2005-07-27 JP JP2005217442A patent/JP4938259B2/ja not_active Expired - Lifetime
- 2005-07-27 NO NO20053644A patent/NO20053644L/no not_active Application Discontinuation
- 2005-07-27 JP JP2005217433A patent/JP2006022107A/ja active Pending
- 2005-07-27 NO NO20053645A patent/NO20053645L/no not_active Application Discontinuation
- 2005-08-09 IL IL170181A patent/IL170181A/en active Protection Beyond IP Right Term
- 2005-08-11 RU RU2005125569/04A patent/RU2005125569A/ru not_active Application Discontinuation
- 2005-08-12 RU RU2005125645/04A patent/RU2005125645A/ru not_active Application Discontinuation
- 2005-09-16 BG BG109297A patent/BG65803B1/bg unknown
-
2006
- 2006-07-28 CY CY20061101045T patent/CY1105517T1/el unknown
-
2007
- 2007-04-10 JP JP2007102379A patent/JP4769756B2/ja not_active Expired - Fee Related
- 2007-12-13 US US12/000,512 patent/US7692028B2/en not_active Expired - Fee Related
-
2010
- 2010-01-11 CY CY20101100031T patent/CY1109718T1/el unknown
- 2010-02-17 US US12/656,808 patent/US8034958B2/en not_active Expired - Fee Related
-
2011
- 2011-08-31 US US13/222,477 patent/US8492416B2/en not_active Expired - Fee Related
-
2016
- 2016-03-08 NO NO2016005C patent/NO2016005I1/no unknown
- 2016-03-09 BE BE2016C012C patent/BE2016C012I2/fr unknown
- 2016-03-11 LU LU92993C patent/LU92993I2/xx unknown
- 2016-04-13 HU HUS1600017C patent/HUS1600017I1/hu unknown
- 2016-05-04 LT LTPA2016013C patent/LTC1265862I2/lt unknown
- 2016-05-25 FR FR16C1001C patent/FR16C1001I2/fr active Active
- 2016-05-27 NL NL300815C patent/NL300815I2/nl unknown
- 2016-06-30 CY CY2016022C patent/CY2016022I2/el unknown
-
2023
- 2023-06-20 NO NO2023025C patent/NO2023025I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528828A5 (enExample) | ||
| JP2023078293A (ja) | 生物活性剤に関する方法および組成物 | |
| JP2010532340A5 (enExample) | ||
| CN106279300B (zh) | Rig-i配体及其生产方法 | |
| CA2454306A1 (en) | Substituted dihydro 3-halo-1h-pyrazole-5-carboxylates their preparation and use | |
| RU96122244A (ru) | Способ диастереоселективного синтеза аналогов нуклеозидов | |
| JP2005502658A5 (enExample) | ||
| JP2010500343A5 (enExample) | ||
| DK1678119T3 (da) | Fremgangsmåde til fremstilling af 2-dihalogenacyl-3-amino-acrylsyreestere og 3-dihalogenmethyl-pyrazol-4-carboxylsyreestere | |
| JP2002529532A5 (enExample) | ||
| JP2009541236A5 (enExample) | ||
| JP2010540477A5 (enExample) | ||
| JP2001519410A5 (enExample) | ||
| JP2004517098A5 (enExample) | ||
| RU2002113104A (ru) | Способы стабилизации соединений на основе бензимидазола | |
| BRPI0409049A (pt) | métodos de preparação de um composto, composição e composição cristalina | |
| DE50113943D1 (de) | 4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung | |
| ATE298746T1 (de) | Verfahren zur herstellung von substituierten benzimidazolverbindungen | |
| JP2012518649A5 (enExample) | ||
| JP2004524388A5 (enExample) | ||
| JP2006520398A5 (enExample) | ||
| DE602006021411D1 (de) | Verfahren zur herstellung von optional 2-substituierten 1,6-dihydro-6-oxo-4-pyrimidincarboxylsäuren | |
| JP2004525178A5 (enExample) | ||
| RU2454419C2 (ru) | Новые ациклические, замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний | |
| DE602004001969D1 (de) | Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung |